11 November 2020
HFpEF—pronounced 'heff peff' - is a condition whereby heart muscles are too stiff, preventing the organ's chambers from filling properly with blood. Symptoms include shortness of breath, swelling in the legs, ankles, feet or in the lower back or abdomen, and extreme tiredness. It affects half of the 920,000 people in the UK with heart failure but frequently goes undiagnosed.
The National Institute of Clinical Excellence (NICE) recommends that 'integrated' care should be provided for HFpEF, bringing together specialist clinicians with GPs and primary care, and including support for patients to help them manage their condition.
In a new study published today in the British Journal of General Practice, the researchers argue that the problems they have identified may help to explain why the condition is difficult to diagnose and why there is a persistent gap between the national guidance on managing the condition and the kind of service patients receive.
The problems were uncovered in a study carried out in the East of England, Greater Manchester and the West Midlands, in which 50 people with HFpEF, nine carers and 73 clinicians, were interviewed. The clinicians included GPs and nurses from 26 GP practices, as well as heart failure specialist nurses and cardiologists from nine hospitals.
The team used a theoretical framework known as Normalisation Process Theory to make sense of the large amount of data generated by the interviews. The theory considers how healthcare interventions are integrated into routine practice, or 'normalised'.
For any intervention to be routinely adopted, there needs to be a clear understanding—and differentiation between—aspects of the illness, tests and treatments, for example. The team found that this understanding is often missing for the clinicians dealing with patients experiencing HFpEF. In addition, some patients described how they were not aware they had the condition despite severe symptoms and, in some cases, multiple hospital admissions, and were unclear on how the condition can be best managed.
The data confirmed that diagnosis and treatment of HFpEF is not part of everyday practice in general practice, and that the condition was not widely visible, understood, or diagnosed within primary care. The researchers identified three clear tensions that contributed to this.
First, diagnosis of HFpEF is difficult and often delayed. A common method for identifying heart disorders is through the use of an echocardiogram, but in patients with HFpEF, the 'ejection fraction' - the percentage of blood leaving the heart each time it contracts—often appears normal or almost normal, confusing diagnosis. Many clinicians indicated a need for specialist opinion but referral systems were varied and inconsistent.
Patients' descriptions of their diagnoses frequently conveyed a convoluted and protracted series of hospital admissions or visits to specialist clinics. Diagnosis was often slowed down by the presence of other co-existing health conditions, non-specific symptoms and breathlessness.
Second, there are varying perceptions of this complex condition and the data show little shared understanding between clinicians, patients and carers. Several clinicians indicated there is professional scepticism with the label of HFpEF, and most expressed a need for more knowledge and understanding of the condition.
Many patients had partial or incomplete knowledge of the condition, which often related to existing heart problems. Few patients provided a clear understanding of their heart failure.
Finally, once patients are diagnosed, the services they can access are variable. Roles and responsibilities are not well understood and there are big gaps in care. A sense of clinical inertia was revealed within some patient and clinician accounts, apparently due to a lack of evidence-based practice and a feeling that there was little that could be done.
"Our research paints a picture of a cloud of clinical uncertainty surrounding the diagnosis and treatment of HFpEF, which often leads to a failure to manage the condition," said lead author Dr. Emma Sowden from the University of Manchester. "Patients' descriptions of their diagnoses suggest they are far more convoluted than the clinical guidelines spell out, leading to a protracted series of hospital admissions or specialist visits."
Professor Christi Deaton, Chief Investigator from the Department of Public Health and Primary Care at the University of Cambridge and a Fellow at Wolfson College, added: "We heard some clinicians asking: what's the point of diagnosis if there is no specific treatment? But identification of HFpEF is critical if we are going to develop new treatments and ways for patients to better manage their condition, and there are actions that we can take now."
The study is part of a larger programme of work on HFpEF, which aims to improve the management of people with HFpEF in primary care. The programme is funded by the NIHR School for Primary Care Research.
Living with HFpEF: Mike and Anna
Mike and Anna, who live in Mossley, Greater Manchester, are, in their own words, 'glass-half-full' people. But Mike has heart failure with HFpEF.
Until he retired on health grounds two years ago, aged 66, Mike was a police community support officer, a job that he loved. Anna, his wife of 17 years, is a retired health visitor and nurse midwife—"It's a good thing I have medical knowledge," she said. "I've needed it."
HFpEF comes on slowly, Mike explained. He has had heart problems for 24 years and despite a pacemaker and later a stent, and now a regime of 13 different medications a day, his symptoms don't seem any better. He is tired all the time, breathless and his activity is severely limited.
"From a personal point of view it is so frustrating to go from being someone who swam three times a week and walked eight miles a day to being all washed up," said Mike.
"My GP says it's multifactorial. But no matter what you say to a consultant, [they say] it's because I eat too much. You do get a condescending attitude about food. I get conflicting advice from various professionals about what I should and shouldn't be doing. They say exercise and lose weight, but I set all the alarms off on the monitors when the cardiac physiotherapist was assessing me and she told me to stop right there.
"I do end up asking: why am I taking all these medications and I still feel so bad? I'm treading water just waiting for the next consultation."
Anna is determined to help Mike get access to treatment that might improve his quality of life.
"I'm like a dog with a bone," said Anna. "I said, why is he still breathless if he has the stent and all the medications? I think I was the one who found out about the possibility of HFpEF, and I researched the medical terminology, like diastolic dysfunction and what ejection fraction means.
"HFpEF seems to be classed as a second class citizen of heart failure. The medics don't tell you that you have it and they don't tell you it's serious. It's frustrating for the doctors too, because the test results are not clear and they don't know how to treat it. But we have had to fight for every little bit [of help]."
Lack of understanding of common heart condition leads to missed treatment opportunities
Poor awareness of a condition known as Heart Failure with preserved Ejection Fraction (HFpEF) - the cause of a half of all cases of heart failure in England could be hindering opportunities to improve care for patients, say researchers from the Universities of Cambridge, Manchester, and Keele.
 Foto: CC0 Public DomainHFpEF is a condition whereby heart muscles are too stiff, preventing the organ’s chambers from filling properly with blood. |
The National Institute of Clinical Excellence (NICE) recommends that 'integrated' care should be provided for HFpEF, bringing together specialist clinicians with GPs and primary care, and including support for patients to help them manage their condition.
In a new study published today in the British Journal of General Practice, the researchers argue that the problems they have identified may help to explain why the condition is difficult to diagnose and why there is a persistent gap between the national guidance on managing the condition and the kind of service patients receive.
The problems were uncovered in a study carried out in the East of England, Greater Manchester and the West Midlands, in which 50 people with HFpEF, nine carers and 73 clinicians, were interviewed. The clinicians included GPs and nurses from 26 GP practices, as well as heart failure specialist nurses and cardiologists from nine hospitals.
The team used a theoretical framework known as Normalisation Process Theory to make sense of the large amount of data generated by the interviews. The theory considers how healthcare interventions are integrated into routine practice, or 'normalised'.
For any intervention to be routinely adopted, there needs to be a clear understanding—and differentiation between—aspects of the illness, tests and treatments, for example. The team found that this understanding is often missing for the clinicians dealing with patients experiencing HFpEF. In addition, some patients described how they were not aware they had the condition despite severe symptoms and, in some cases, multiple hospital admissions, and were unclear on how the condition can be best managed.
The data confirmed that diagnosis and treatment of HFpEF is not part of everyday practice in general practice, and that the condition was not widely visible, understood, or diagnosed within primary care. The researchers identified three clear tensions that contributed to this.
First, diagnosis of HFpEF is difficult and often delayed. A common method for identifying heart disorders is through the use of an echocardiogram, but in patients with HFpEF, the 'ejection fraction' - the percentage of blood leaving the heart each time it contracts—often appears normal or almost normal, confusing diagnosis. Many clinicians indicated a need for specialist opinion but referral systems were varied and inconsistent.
Patients' descriptions of their diagnoses frequently conveyed a convoluted and protracted series of hospital admissions or visits to specialist clinics. Diagnosis was often slowed down by the presence of other co-existing health conditions, non-specific symptoms and breathlessness.
Second, there are varying perceptions of this complex condition and the data show little shared understanding between clinicians, patients and carers. Several clinicians indicated there is professional scepticism with the label of HFpEF, and most expressed a need for more knowledge and understanding of the condition.
Many patients had partial or incomplete knowledge of the condition, which often related to existing heart problems. Few patients provided a clear understanding of their heart failure.
Finally, once patients are diagnosed, the services they can access are variable. Roles and responsibilities are not well understood and there are big gaps in care. A sense of clinical inertia was revealed within some patient and clinician accounts, apparently due to a lack of evidence-based practice and a feeling that there was little that could be done.
"Our research paints a picture of a cloud of clinical uncertainty surrounding the diagnosis and treatment of HFpEF, which often leads to a failure to manage the condition," said lead author Dr. Emma Sowden from the University of Manchester. "Patients' descriptions of their diagnoses suggest they are far more convoluted than the clinical guidelines spell out, leading to a protracted series of hospital admissions or specialist visits."
Professor Christi Deaton, Chief Investigator from the Department of Public Health and Primary Care at the University of Cambridge and a Fellow at Wolfson College, added: "We heard some clinicians asking: what's the point of diagnosis if there is no specific treatment? But identification of HFpEF is critical if we are going to develop new treatments and ways for patients to better manage their condition, and there are actions that we can take now."
The study is part of a larger programme of work on HFpEF, which aims to improve the management of people with HFpEF in primary care. The programme is funded by the NIHR School for Primary Care Research.
Living with HFpEF: Mike and Anna
Mike and Anna, who live in Mossley, Greater Manchester, are, in their own words, 'glass-half-full' people. But Mike has heart failure with HFpEF.
Until he retired on health grounds two years ago, aged 66, Mike was a police community support officer, a job that he loved. Anna, his wife of 17 years, is a retired health visitor and nurse midwife—"It's a good thing I have medical knowledge," she said. "I've needed it."
HFpEF comes on slowly, Mike explained. He has had heart problems for 24 years and despite a pacemaker and later a stent, and now a regime of 13 different medications a day, his symptoms don't seem any better. He is tired all the time, breathless and his activity is severely limited.
"From a personal point of view it is so frustrating to go from being someone who swam three times a week and walked eight miles a day to being all washed up," said Mike.
"My GP says it's multifactorial. But no matter what you say to a consultant, [they say] it's because I eat too much. You do get a condescending attitude about food. I get conflicting advice from various professionals about what I should and shouldn't be doing. They say exercise and lose weight, but I set all the alarms off on the monitors when the cardiac physiotherapist was assessing me and she told me to stop right there.
"I do end up asking: why am I taking all these medications and I still feel so bad? I'm treading water just waiting for the next consultation."
Anna is determined to help Mike get access to treatment that might improve his quality of life.
"I'm like a dog with a bone," said Anna. "I said, why is he still breathless if he has the stent and all the medications? I think I was the one who found out about the possibility of HFpEF, and I researched the medical terminology, like diastolic dysfunction and what ejection fraction means.
"HFpEF seems to be classed as a second class citizen of heart failure. The medics don't tell you that you have it and they don't tell you it's serious. It's frustrating for the doctors too, because the test results are not clear and they don't know how to treat it. But we have had to fight for every little bit [of help]."
More news about "MEDICA":
21 September 2020
MEDICA and COMPAMED 2020 to be launched as ‘virtual.MEDICA’ and ‘virtual.COMPAMED’
MEDICA 2020 and COMPAMED 2020, the world-leading information and communication platforms for the medical technology industry and supplier industry for the medical technology industry, will take place entirely online from 16 to 19 November. Within the framework of 'virtual.MEDICA' and 'virtual.COMPAMED', decision-makers from all sectors of the healthcare industry can then expect a comprehensive range of products and services at virtual.MEDICA.de and virtual.COMPAMED.de consisting of three focal areas: The Conference Area (conference and forum program), the Exhibition Space (for exhibitors and product innovations) and the Networking Plaza (networking/ matchmaking). The next events, MEDICA 2021 and COMPAMED 2021, will be held as a hybrid event next year. The hybrid concept consists of combining live platforms for professional visitors to the Düsseldorf trade fair centre and digital offers. (more…)2 July 2020
The MEDICA, the world’s leading medical trade fair held in Düsseldorf, was one of the very first events across all industries to offer young companies in their founding phase special programme formats to present their concepts many years ago. It has subsequently become the international number one for health start-ups too. The creative and predominantly digitally driven start-up scene will be the centre of attention once again at MEDICA 2020 (run time: 16 to 19 November). This is because, following the Corona pandemic, mobile and easily applicable solutions for linking the actors in the healthcare system have become even more important. (more…)19 June 2020
Globally, no sector has been placed under the magnifying glass more than the healthcare sector due to the Corona pandemic. Hospitals, outpatient clinics, practice-based physicians and care facilities have experienced a sudden increased demand for medical and laboratory technology, a wide variety of medical products, digital health applications and, most of all, personal protective equipment. Under these conditions, the plans for the world’s biggest medical trade fair MEDICA 2020 and the number one trade fair for suppliers of the medical technology industry, COMPAMED 2020, held in parallel, are revving up to full throttle. Both events will take place from 16 to 19 November in Düsseldorf – closely interlinked with extensive digital offers and services. (more…)8 March 2019
Messe Düsseldorf India has acquired the FAMDENT Shows, one of the leading Indian fairs for dental medicine. This means the event will become a member of the MEDICAlliance, the umbrella brand for all global healthcare exhibition activities of the Messe Düsseldorf Group. (more…)28 January 2019
Medical Fair India with new “rehaindia” feature
From 21 – 23 February 2019 the Indian health industry elite will meet at the 25th Medical Fair India at the Pragati Maidon Exhibition Center in New Delhi. A new feature this year is rehaindia (powered by Rehacare) with ranges for rehabilitation and nursing care. (more…)
| FAIR NAVIGATOR PHARMA / MEDICAL TECHNOLOGY | |
|---|---|
|
| E-PAPER MEDICA |
 |